Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma (Q33828783)

29 July 2017

Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma (English)

1 reference

29 July 2017

1 reference

7

David Dingli

1 reference

29 July 2017

6

Angela Dispenzieri

1 reference

29 July 2017

8

Robert A Kyle

1 reference

29 July 2017

3

Martha Q Lacy

1 reference

29 July 2017

2

S Vincent Rajkumar

1 reference

29 July 2017

9

Morie A Gertz

1 reference

29 July 2017

4

Suzanne R Hayman

1 reference

29 July 2017

5

Francis K Buadi

1 reference

29 July 2017

10

Shaji Kumar

1 reference

29 July 2017

1

Shirshendu Sinha

1 reference

PubMed ID

19958361

29 July 2017

language of work or name

English

0 references

publication date

3 December 2009

1 reference

British Journal of Haematology

29 July 2017

1 reference

29 July 2017

148

1 reference

29 July 2017

6

1 reference

29 July 2017

853-858

1 reference

Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

28 July 2018

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

A phase 2 study of bortezomib in relapsed, refractory myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Review of 1027 patients with newly diagnosed multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

VAD-based regimens as primary treatment for multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Primary dexamethasone treatment of multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Controversies regarding the use of dexamethasone in patients with multiple myeloma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Improved survival in multiple myeloma and the impact of novel therapies

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Recent major improvement in long-term survival of younger patients with multiple myeloma

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

International uniform response criteria for multiple myeloma.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Prednisone pulse therapy for refractory myeloma.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2864312

High-dose glucocorticoid treatment of resistant myeloma

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19958361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19958361

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2141.2009.08023.X

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

PubMed ID

19958361